These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 24169807

  • 1. Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
    McGill JB, Barnett AH, Lewin AJ, Patel S, Neubacher D, von Eynatten M, Woerle HJ.
    Diab Vasc Dis Res; 2014 Jan; 11(1):34-40. PubMed ID: 24169807
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Jan; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    Owens DR, Swallow R, Dugi KA, Woerle HJ.
    Diabet Med; 2011 Nov; 28(11):1352-61. PubMed ID: 21781152
    [Abstract] [Full Text] [Related]

  • 6. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 7. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 8. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec 01; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, Lee HW, Lee DH, Kim J, Chung CH, Park TS, Kim BJ, Park SW, Park HK, Lee KJ, Kim SW, Park JH, Ko KP, Kim CH, Lee H, Jang HC, Park KS.
    Diabetes Obes Metab; 2017 May 01; 19(5):635-643. PubMed ID: 28026912
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
    Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ.
    Diabetes Care; 2015 Feb 01; 38(2):e15-7. PubMed ID: 25614693
    [No Abstract] [Full Text] [Related]

  • 12. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ.
    Lancet; 2012 Aug 04; 380(9840):475-83. PubMed ID: 22748821
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 14. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
    McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ.
    Diabetes Care; 2013 Feb 01; 36(2):237-44. PubMed ID: 23033241
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z, Yang JK, Tong N, Yan S, Zhang X, Gong Y, Woerle HJ.
    Curr Med Res Opin; 2013 Aug 01; 29(8):921-9. PubMed ID: 23672632
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ.
    Curr Med Res Opin; 2012 Sep 01; 28(9):1465-74. PubMed ID: 22816729
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE.
    Can J Diabetes; 2016 Feb 01; 40(1):50-7. PubMed ID: 26474870
    [Abstract] [Full Text] [Related]

  • 20. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA.
    Diabetes Obes Metab; 2012 Apr 01; 14(4):348-57. PubMed ID: 22145698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.